Breaking News

Thursday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Conference/Events
Siga Technologies to host business news update conference call » 16:25
08/06/20
08/06
16:25
08/06/20
16:25
SIGA

Siga Technologies

$6.49 /

-0.23 (-3.42%)

Dr. Gomez, CEO and CFO…

Dr. Gomez, CEO and CFO Luckshire hold a business news update conference call on August 6 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
SIGA Siga Technologies
$6.49 /

-0.23 (-3.42%)

Conference/Events
Siga Technologies to host business news update conference call » 10:42
08/06/20
08/06
10:42
08/06/20
10:42
SIGA

Siga Technologies

$6.72 /

+ (+0.00%)

Dr. Gomez, CEO and CFO…

Dr. Gomez, CEO and CFO Luckshire hold a business news update conference call on August 6 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
SIGA Siga Technologies
$6.72 /

+ (+0.00%)

Over a week ago
Hot Stocks
Siga Technologies files MAA for oral tecovirimat » 08:17
07/30/20
07/30
08:17
07/30/20
08:17
SIGA

Siga Technologies

$6.65 /

-0.09 (-1.34%)

SIGA Technologies…

SIGA Technologies announced that it has filed a Marketing Authorisation Application with the European Medicines Agency for oral tecovirimat, the same formulation that was approved by the U.S. Food and Drug Administration in July 2018 under the name TPOXX. The MAA was filed under the centralized application process, which, upon approval, and will enable sales and marketing of oral tecovirimat in all EU member states, as well as Norway, Iceland, and Liechtenstein. SIGA has filed its application for oral tecovirimat seeking a broader label indication covering the treatment of smallpox, monkeypox, cowpox, and complications from Vaccinia infection. SIGA is targeting approval for the second half of 2021. On July 13, 2018, the FDA approved oral TPOXX for the treatment of smallpox to mitigate the impact of a potential outbreak or bioterror attack. TPOXX, a small-molecule antiviral treatment for smallpox, is the first therapy specifically approved for this indication, and was developed through funding and collaboration with the Biomedical Advanced Research and Development Authority at the U.S. Department of Health and Human Services, as well as early stage development supported by the National Institutes of Health, U.S. Centers for Disease Control and Prevention, and Department of Defense. The US currently maintains a stockpile of 1.7 million courses of TPOXX. In June 2019, SIGA entered into an international promotion agreement with Meridian. Under the agreement, Meridian will promote the sale of oral tecovirimat for the treatment of smallpox in all international markets, except the United States and South Korea. SIGA will continue to own all rights to the product and its related intellectual property. On June 1, 2020, SIGA announced its first international sale with 2,500 courses delivered to the Canadian Department of National Defence.

ShowHide Related Items >><<
SIGA Siga Technologies
$6.65 /

-0.09 (-1.34%)

Over a month ago
Hot Stocks
Siga Technologies announces $32M in Tpoxx deliveries to HHS » 16:08
06/25/20
06/25
16:08
06/25/20
16:08
SIGA

Siga Technologies

$6.17 /

+0.21 (+3.52%)

Siga Technologies…

Siga Technologies announced the deliveries of oral Tpoxx to the U.S. Department of Health and Human Services, or HHS. These deliveries, valued at approximately $32M, are the initial deliveries of the contract option exercises announced in April. The previously-announced option exercises under the 2018 contract with the Biomedical Advanced Research and Development Authority, or BARDA, part of the Office of the Assistant Secretary for Preparedness and Response at HHS, are worth a total of approximately $101.3M for the procurement of oral Tpoxx. Deliveries of oral Tpoxx to maintain national preparedness under these option exercises are expected to be completed by April 2021. SIGA's full 19C BARDA Contract has up to approximately $414M of procurement-related options remaining for future exercise.

ShowHide Related Items >><<
SIGA Siga Technologies
$6.17 /

+0.21 (+3.52%)

Hot Stocks
Siga Technologies says DoD increases funding to develop PEP indication for TPOXX » 07:39
06/15/20
06/15
07:39
06/15/20
07:39
SIGA

Siga Technologies

$5.62 /

-0.04 (-0.71%)

SIGA Technologies…

SIGA Technologies announced that the United States Department of Defense, via the Joint Program Executive Office for Chemical, Biological, Radiological, and Nuclear Defense's Joint Project Manager for Chemical, Biological, Radiological, and Nuclear Medical, has increased research and development funding to approximately $23M in connection with the DoD contract to support work necessary to gain a potential label expansion from the U.S. Food and Drug Administration for TPOXX for Post-Exposure Prophylaxis in addition to the current approved labeling for the treatment of smallpox. The use of TPOXX for PEP could provide significant potential benefit in the event of a smallpox pandemic or outbreak. While vaccines would play an important role in containing the spread of smallpox, they are only effective if administered prior to infection or no later than four days after infection. However, symptoms of smallpox do not typically appear until approximately 14 days post-infection, and there is currently no diagnostic test to determine infection prior to symptom onset. Given the uncertainty of an individual's infection status in that two-week period, and the highly contagious nature of smallpox, the administration of a vaccine in combination with TPOXX could be an important strategy for reducing morbidity and mortality in a smallpox outbreak. Dosing of TPOXX in the PEP indication is expected to be 28 days rather than the 14-day dosing currently recommended for its use in treating patients with active smallpox infections. This would increase the amount of TPOXX used for each exposed person compared with each infected person.

ShowHide Related Items >><<
SIGA Siga Technologies
$5.62 /

-0.04 (-0.71%)

Hot Stocks
Siga Technologies announces international delivery of oral TPOXX » 09:16
06/01/20
06/01
09:16
06/01/20
09:16
SIGA

Siga Technologies

$6.00 /

-0.09 (-1.48%)

SIGA Technologies…

SIGA Technologies announced its first international delivery of TPOXX, with 2,500 courses delivered to the Canadian Department of National Defence. On April 3, 2020, the Company previously announced that the CDND is expected to purchase up to 15,325 courses of oral TPOXX over four years for a total value of $14.3 million. Remaining purchases of 12,825 courses, at the option of the CDND, are expected to occur after regulatory approval of oral TPOXX by Health Canada. Meridian Medical Technologie, SIGA's partner for international promotion of TPOXX, is the counterparty to the Canadian Contract and SIGA is responsible for the manufacture and delivery of oral TPOXX. In addition to the Canadian product delivery, SIGA also expects to make deliveries of oral TPOXX to the U.S. Government this month. As previously disclosed, SIGA expects to deliver $101.3 million of oral TPOXX to the U.S. Government by April 2021, with deliveries starting this month. These deliveries will be in connection with the recent option exercises under its 2018 Biomedical Advanced Research and Development Authority contract. In addition to the options recently exercised, SIGA's full 19C BARDA Contract has up to $414 million of procurement-related options remaining for future exercise.

ShowHide Related Items >><<
SIGA Siga Technologies
$6.00 /

-0.09 (-1.48%)

Over a quarter ago
Conference/Events
Siga Technologies to hold a business news update conference call » 16:25
05/06/20
05/06
16:25
05/06/20
16:25
SIGA

Siga Technologies

$5.82 /

+0.03 (+0.52%)

Conference call to…

Conference call to provide a business update, as well as discuss 1Q reported earnings on May 6 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
Conference/Events
Siga Technologies to hold a business news update conference call » 08:34
05/06/20
05/06
08:34
05/06/20
08:34
SIGA

Siga Technologies

$5.79 /

-0.09 (-1.53%)

Conference call to…

Conference call to provide a business update, as well as discuss 1Q reported earnings on May 6 at 4:30 pm. Webcast Link

ShowHide Related Items >><<
Hot Stocks
Siga announces BARDA exercise of contract options valued at $101.3M » 16:37
04/29/20
04/29
16:37
04/29/20
16:37
SIGA

Siga Technologies

$5.77 /

+0.16 (+2.85%)

SIGA Technologies…

SIGA Technologies announced the exercise of options under its 2018 Biomedical Advanced Research and Development Authority contract worth a total of approximately $101.3 million for the procurement of oral TPOXX for the treatment of smallpox. Deliveries of oral TPOXX to maintain national preparedness under these option exercises are expected to start in the second quarter of 2020 and be completed by April 2021. With the above-mentioned exercise of options, all procurement options under CLIN 9 (contract line item number 9) of the 19C BARDA Contract have been exercised. SIGA's full 19C BARDA Contract has up to $414 million of procurement-related options remaining for future exercise. "The intent of the Request for Proposal for this BARDA Contract was to maintain the existing stockpile of TPOXX and the exercise of these options is an important step toward ensuring that the U.S. Government can effectively meet this critical goal," said Dr. Phil Gomez, CEO of SIGA Technologies. "The ongoing COVID-19 pandemic has dramatically underscored the importance of national preparedness. The exercise emphasizes the critical value of our smallpox anti-viral treatment in that effort, and underscores SIGA's commitment to working with BARDA and the Office of the Assistant Secretary for Preparedness and Response (ASPR) to protect against the threat of a potential smallpox outbreak or bioterror attack."

ShowHide Related Items >><<
Hot Stocks
Siga Technologies announces award of international contract for oral TPOXX » 10:19
04/03/20
04/03
10:19
04/03/20
10:19
SIGA

Siga Technologies

$4.74 /

-0.03 (-0.63%)

SIGA Technologies (SIGA)…

SIGA Technologies (SIGA) announced that the Canadian Department of National Defence has awarded a contract to Meridian Medical Technologies, in which it will purchase up to 15,325 courses of oral TPOXX over four years for a total value of $14.3M, with an initial purchase of 2,500 courses for $2.3M. SIGA expects delivery of up to an additional 12,825 courses under the Canadian Contract to occur after regulatory approval in Canada. SIGA previously received a contract from the CDND to fund this regulatory submission. The Company is currently targeting a Canadian regulatory filing in the second half of 2020, with regulatory approval anticipated in 2021. This contract represents the first international order for TPOXX. As part of a previously announced promotion agreement, Meridian is the counterparty to the Canadian Contract and SIGA is responsible for the manufacture and delivery of product. On July 13, 2018, the FDA approved oral TPOXX for the treatment of smallpox to mitigate the impact of a potential outbreak or bioterror attack. TPOXX, a small-molecule antiviral treatment for smallpox, is the first therapy specifically approved for this indication, and was developed through funding and collaboration with the Biomedical Advanced Research and Development Authority at the U.S. Department of Health and Human Services, as well as early stage development supported by the National Institutes of Health, U.S. Centers for Disease Control and Prevention, and Department of Defense. The US currently maintains a stockpile of 1.7 million courses of TPOXX. In June 2019, SIGA entered into an international promotion agreement with Meridian. Under the agreement, Meridian will promote the sale of oral TPOXX for the treatment of smallpox in all international markets, except the United States and South Korea. SIGA will continue to own all rights to the product and its related intellectual property.

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.